The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Life-years and quality-adjusted outcomes with belantamab mafodotin in RRMM: DREAMM-7 analysis
Attaya Suvannasankha, MD, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, discusses findings from the Phase III DREAMM-7 (NCT04246047) analysis showing that belantamab mafodotin, bortezomib, and dexamethasone improve life years and quality-adjusted life years compared with other standard regimens in relapsed/refractory multiple myeloma (RRMM). She emphasizes how these results add a patient-centered value perspective to treatment selection beyond efficacy alone. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Treatment landscape of myeloma has changed a lot. This year, we welcome back belantamab mafodotin, which was approved based on Phase II data several years back, but since then had been withdrawn from the market. DREAMM-7 is the phase three study that has led to an approval of belantamab mafodotin, bortezomib and dexamethasone because of the superior progression-free survival and tend towards improvement in overall survival comparing to the daratumumab, bortezomib and dexamethasone...
Treatment landscape of myeloma has changed a lot. This year, we welcome back belantamab mafodotin, which was approved based on Phase II data several years back, but since then had been withdrawn from the market. DREAMM-7 is the phase three study that has led to an approval of belantamab mafodotin, bortezomib and dexamethasone because of the superior progression-free survival and tend towards improvement in overall survival comparing to the daratumumab, bortezomib and dexamethasone. So now that we have this regimen, we wanted to understand what is the impact on the quality of life and also the life years gain on patients with relapsed myeloma in that space when there are also other regimens that are usable in that space. So this study is comparing the quality adjusted life years and life years gain using belantamab mafodotin, bortezomib, dexamethasone to compare with other treatments such as the pomalidomide, bortezomib, dexamethasone, carfilzomib dexamethasone, carfilzomib, dexamethasone, daratumumab, and also isatuximab, carfilzomib dexamethasone. So based on the comparison across, we saw that the quality of life, the quality adjusted life years, and also the life years gained were more significant with the belantamab mafodotin, bortezomib and dexamethasone. So now this is putting not only efficacy, but also value in way of the quality on the patient’s life after they’re starting on therapy into perspective in helping as physicians are really advising patients of which regimens to use.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
